- Email: [email protected]
Process for the purification of gases containing hydrogen sulphide (CJ Buisman et al, NL)
Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP (...) > Nucleic acid primers and probes for detecting Chlamydia pneumoniae (MB Cerney, US) A b b o t t Laboratories N° wo 97/46709, PCT.
Nucleic acid sequences that are useful for detecting Cklamydia pneumoniae are herein provided. These sequences can be used in hybridizatkm assays or amplification based assays designed to detect the pre~ence of Chlamydia pneum~,niae in a test sample (...) =,i;i~ ++:+C e r > Bloocking expression of virulence factors in S aureus (RP Novick and R Beavis, US) New York University N° W0 97/443,19, PC]-.
> Methods and compositions for determining the tumor suppressor status of cells (A Fattaey, US) Onyx Pharmaceuticals Inc
N° W0 97/45556. PC]-. ,Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting ot a first polynucleotide sequence that encodes a reporter molecule and a second p53 bincling polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.
Vaccir~s > Amelioration of erectile dysfunction (N GonzalezCadavid and J Rajfer, US)
This invention provides peptides whirl1 inhibit agr transcription in S aureus and thereby block the expression of virulence factors in S aureus, pharmaceutical compositions comprising these pepudes, as well as methods fi)r ~reating or preventing an intection or disease caused by 5, aureus using the peptides ~,f the present invention.
> Genaration de molecules replicatives in vivo (H Leblois-Prehaud et al, FR)
> P a t c h e d genes and their uses (MP Scott et al, US)
CNRS, Institut G u s t a v e Roussy N° 2749857, FR.
The keland S Stanford Junior University and the Regents of the University of California N° WO 97!45541, POT.
~lethods for isolating patched genes, particularly mammalian patched genes, including the nlou.~e and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expressic'n of patched is associated with the <)ccnrrence of h u m a n c a n c e r s , particularly basal cell carcinomas of the skin. (...). The patched nucleic acid compositions find use in identifying homologous or related pr oteins and the DNA sequences encoding such proteins ; in producing compositions tbar modulate the expression or fimction of the protein : and smdring ass(~ciated 15 physiological paJ~ways (..+)
The inventors N° WO 97/42965, PCT.
Tl~erapies: '{i {] !!I} i:~tl e S E![
cettulaire
La pr~sente invention cmlcerne des mol&ules d'ADN circulaires et rdplicatives, utilisables en th&apie gdnique, ainsi q u ' u n e mdthode particulibrement efficace pour leur g~n&ation in situ ~ partir d'un vecteur viral. > Vectors comprising sar elements (M Agarwal et al, IN, HR, US) Novartis AG, Systemix Inc and the inventors N° WO 97/46687, PC].
Scaffold attachment regions are found to increase gene expression in transduced cells, and to be therefore useful, eg, in gene therapy
University of British Columbia N° W0 97/46671, PCT.
Pharmaceutical compositions for the treatment of pathologic conditions associated with the overexpression of ICAM-1 in a host. These pharmaceutical compositions comprise an effective amoung of an ICAM-1 antisense molecule encapsulated in a lipid mixture... > Pseudo-particules virales utiles en tant que vecteurs de d~livrance d'acide nucldique (MA Bloch, FR) Pasteur Merieux Serums et Vaccins et I'inventeur N° W0 97/46693, PC]-.
l:invention a pour objet une psendo-patticule virale (VLP) non-infectieuse qui comprend une capside ddlimitant tin espace interne et constitute au moins par tout ou partie de la prot~ine Ll et 6ventuellement tout ou partie de la prot~ine E2 d'un papillomavirus, et une mol6cule d'acide nuch?ique contenue dans ledit espace interne ; la molecule d'acide nuclSique comportant une r~gion co ~ dant pour une protdine d'inrdr£'t, notaJrmlent un antigone ou une cytokine (...) > Mini-adenoviral vector (WW Zhang et al, CN, US} Baxter International Inc and the inventors N° W0 97/45550. PCT.
Fhis invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including gene trartsfer, gene therapy,, and gene vaccination (...)
CI!IMIE-GENIE lOdE
8i~)~lest tides > Biological insect control agent (RE Duncan et al,
RU} Z e n e c a Ltd, C o m m o n wealth Scientific & Industrial Research Organisation and the inventors N° W0 97/44355, PCT.
t:;l! poilu !} 0n > Immobilized cell bioreactor and method of biodegrading pollutants in a fluid (AD Powers, US) Alliedsignal Inc N° W0 97/43218, PCT.
> Process for the purification of gases containing hydrogen sulphide (CJ Buisman et al, NL) Paques BV and the inventors N° WO 97/43033, PCT.
The invention relates to a process for scrubbing a gas c o n t a i n i n g hydrogen sulphide and/or carbonyl sulphide, in which the spent scrubbing liquid is treated with autotrophic sulphideoxidising bacteria capable of o~idising at high pH, and elemental sulphur is obtained, the elemental sulphur is separated and the treated scrubbing liquid is recycled to the gas scrubbing step
/ I~1-"
[: h imie 2 +] ir~111i I1 a { t) i r
> Multi-reactor synthesizer and method for combinatorial chemisfw (ML Moore and DS Yamashita, US) SmithKline Beecham Corp and the inventors N° WO 97/45455, PCT.
?.:;y ,St ~. m e ~ e .~ e i i ,,P'a f'~c e
> Enhanced efficacy of liposomal antisense delivery (SK Klimuk et al, CA)
N° W0 97/44361, POT.
The invention provides a purified thermostable en.zyme derived from the atchad bacterium AEPIIa (...)
> Endoglucanases (DE Lain and EJ Mathur, US) Recombinant E]iocatalysis Inc and the inventors
TECHNOLOGIE Genie > Method for constructing transformed yeast cells, that not contain a selective marker gene (A Toshihiko et al, JP) Suntory Ltd N° 814165, EP.
> Ribozyme-mediated gene replacement (L Duan et al, US) Thomas Jefferson University and the inventors N° WO 97/44348, POT. BIOFUTUR 176 ,' Mars 1998 43
Nucleic acid sequences that are useful for detecting Cklamydia pneumoniae are herein provided. These sequences can be used in hybridizatkm assays or amplification based assays designed to detect the pre~ence of Chlamydia pneum~,niae in a test sample (...) =,i;i~ ++:+C e r > Bloocking expression of virulence factors in S aureus (RP Novick and R Beavis, US) New York University N° W0 97/443,19, PC]-.
> Methods and compositions for determining the tumor suppressor status of cells (A Fattaey, US) Onyx Pharmaceuticals Inc
N° W0 97/45556. PC]-. ,Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting ot a first polynucleotide sequence that encodes a reporter molecule and a second p53 bincling polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.
Vaccir~s > Amelioration of erectile dysfunction (N GonzalezCadavid and J Rajfer, US)
This invention provides peptides whirl1 inhibit agr transcription in S aureus and thereby block the expression of virulence factors in S aureus, pharmaceutical compositions comprising these pepudes, as well as methods fi)r ~reating or preventing an intection or disease caused by 5, aureus using the peptides ~,f the present invention.
> Genaration de molecules replicatives in vivo (H Leblois-Prehaud et al, FR)
> P a t c h e d genes and their uses (MP Scott et al, US)
CNRS, Institut G u s t a v e Roussy N° 2749857, FR.
The keland S Stanford Junior University and the Regents of the University of California N° WO 97!45541, POT.
~lethods for isolating patched genes, particularly mammalian patched genes, including the nlou.~e and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expressic'n of patched is associated with the <)ccnrrence of h u m a n c a n c e r s , particularly basal cell carcinomas of the skin. (...). The patched nucleic acid compositions find use in identifying homologous or related pr oteins and the DNA sequences encoding such proteins ; in producing compositions tbar modulate the expression or fimction of the protein : and smdring ass(~ciated 15 physiological paJ~ways (..+)
The inventors N° WO 97/42965, PCT.
Tl~erapies: '{i {] !!I} i:~tl e S E![
cettulaire
La pr~sente invention cmlcerne des mol&ules d'ADN circulaires et rdplicatives, utilisables en th&apie gdnique, ainsi q u ' u n e mdthode particulibrement efficace pour leur g~n&ation in situ ~ partir d'un vecteur viral. > Vectors comprising sar elements (M Agarwal et al, IN, HR, US) Novartis AG, Systemix Inc and the inventors N° WO 97/46687, PC].
Scaffold attachment regions are found to increase gene expression in transduced cells, and to be therefore useful, eg, in gene therapy
University of British Columbia N° W0 97/46671, PCT.
Pharmaceutical compositions for the treatment of pathologic conditions associated with the overexpression of ICAM-1 in a host. These pharmaceutical compositions comprise an effective amoung of an ICAM-1 antisense molecule encapsulated in a lipid mixture... > Pseudo-particules virales utiles en tant que vecteurs de d~livrance d'acide nucldique (MA Bloch, FR) Pasteur Merieux Serums et Vaccins et I'inventeur N° W0 97/46693, PC]-.
l:invention a pour objet une psendo-patticule virale (VLP) non-infectieuse qui comprend une capside ddlimitant tin espace interne et constitute au moins par tout ou partie de la prot~ine Ll et 6ventuellement tout ou partie de la prot~ine E2 d'un papillomavirus, et une mol6cule d'acide nuch?ique contenue dans ledit espace interne ; la molecule d'acide nuclSique comportant une r~gion co ~ dant pour une protdine d'inrdr£'t, notaJrmlent un antigone ou une cytokine (...) > Mini-adenoviral vector (WW Zhang et al, CN, US} Baxter International Inc and the inventors N° W0 97/45550. PCT.
Fhis invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including gene trartsfer, gene therapy,, and gene vaccination (...)
CI!IMIE-GENIE lOdE
8i~)~lest tides > Biological insect control agent (RE Duncan et al,
RU} Z e n e c a Ltd, C o m m o n wealth Scientific & Industrial Research Organisation and the inventors N° W0 97/44355, PCT.
t:;l! poilu !} 0n > Immobilized cell bioreactor and method of biodegrading pollutants in a fluid (AD Powers, US) Alliedsignal Inc N° W0 97/43218, PCT.
> Process for the purification of gases containing hydrogen sulphide (CJ Buisman et al, NL) Paques BV and the inventors N° WO 97/43033, PCT.
The invention relates to a process for scrubbing a gas c o n t a i n i n g hydrogen sulphide and/or carbonyl sulphide, in which the spent scrubbing liquid is treated with autotrophic sulphideoxidising bacteria capable of o~idising at high pH, and elemental sulphur is obtained, the elemental sulphur is separated and the treated scrubbing liquid is recycled to the gas scrubbing step
/ I~1-"
[: h imie 2 +] ir~111i I1 a { t) i r
> Multi-reactor synthesizer and method for combinatorial chemisfw (ML Moore and DS Yamashita, US) SmithKline Beecham Corp and the inventors N° WO 97/45455, PCT.
?.:;y ,St ~. m e ~ e .~ e i i ,,P'a f'~c e
> Enhanced efficacy of liposomal antisense delivery (SK Klimuk et al, CA)
N° W0 97/44361, POT.
The invention provides a purified thermostable en.zyme derived from the atchad bacterium AEPIIa (...)
> Endoglucanases (DE Lain and EJ Mathur, US) Recombinant E]iocatalysis Inc and the inventors
TECHNOLOGIE Genie > Method for constructing transformed yeast cells, that not contain a selective marker gene (A Toshihiko et al, JP) Suntory Ltd N° 814165, EP.
> Ribozyme-mediated gene replacement (L Duan et al, US) Thomas Jefferson University and the inventors N° WO 97/44348, POT. BIOFUTUR 176 ,' Mars 1998 43